News

The SECURE-SCD registry, which is collecting de-identified data on individuals with sickle cell disease (SCD) who develop COVID-19, will be expanding to include information on children and adults in Africa. The expansion was funded by a $100,000 grant from the Doris Duke Charitable Foundation (DDCF) awarded to…

Same But Different, a U.K. nonprofit that uses the arts to bring communities together, is holding a calendar photography competition to raise awareness for rare diseases. Under the theme “A Glimmer of Hope,” the competition is a means to “visually express the hope that exists for people affected by…

September is National Sickle Cell Awareness Month, set aside annually to bring attention to the blood disorder and the needs of the community. From securing local government proclamations and hosting awareness events, to distributing information and lighting public spaces red, supporters have begun observing the monthlong event. The theme…

The European Commission has granted orphan drug designation to IMR-687, Imara’s potential new therapy for sickle cell disease (SCD). In the European Union, this designation is given to investigative therapies for rare diseases — those that affect fewer than five in 10,000 people — to…

The U.S. Food and Drug Administration (FDA) has given rare pediatric disease designation to EDIT-301, a potential cell therapy for the treatment of sickle cell disease (SCD). This designation is given to therapies that aim to treat serious or life-threatening disorders that affect fewer than 200,000 people…

Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the search for new medicines for rare disorders and incorporating more patient input into research. The goal is to help the pharmaceutical industry deliver innovative new therapies faster and smarter, the…

Use of medical marijuana to ease pain is associated with fewer visits to the hospital in people with sickle cell disease (SCD), a study suggests. Patients given medical marijuana felt this was an effective treatment for pain relief, and also reported a reduction in the need for opioids.

A Phase 2b clinical trial that is investigating the safety and effectiveness of IMR-687 in people with sickle cell disease (SCD) has dosed its first participant, according to the potential therapy’s developer, Imara. The study, Ardent (NCT04474314), intends to enroll almost 100 adults who have SCD. Recruitment…

The EveryLife Foundation for Rare Diseases has launched a scholarship fund in the U.S. to support individuals with rare disorders who are pursuing personal goals through training and education. The initial phase of the five-year, $1-million #RAREis Scholarship Fund will include 32 scholarships — each totaling $5,000 —…

The Scottish Medicines Consortium (SMC) has approved the use of Xromi (hydroxycarbamide), a liquid form of hydroxyurea, for treating children with sickle cell disease (SCD). Xromi is expected to be used in children older than 2 and younger than 9 who…